A newly filed lawsuit in federal court is bringing renewed attention to Depo-Provera, a widely used injectable contraceptive. The plaintiff claims that the manufacturer failed to provide sufficient warnings about potential risks to patients in the United States, despite similar warnings in other countries.
The case, filed in Georgia by Karen Jennings, alleges that long-term use of Depo-Provera may be linked to the development of brain tumors known as meningiomas. These claims are becoming a central issue in a broader wave of Depo-Provera litigation across the nation.
A Plaintiff’s Story Highlights the Allegations
According to the Depo-Provera lawsuit, Jennings began using Depo-Provera in the early 1990’s as a form of birth control. After years of use, she was diagnosed with an intracranial meningioma in 2022.
Her treatment reportedly included brain surgery followed by ongoing medical care. The complaint states that she continues to experience long-term complications, including neurological symptoms and an inability to work.
The Depo-Provera brain tumor lawsuit alleges that these injuries may be linked to prolonged exposure to the drug and patients were not properly informed of potential risks.
What Is Depo-Provera?
Depo-Provera is an injectable form of birth control that contains medroxyprogesterone acetate, a synthetic hormone. It is generally administered every three months and is often used as a long-term contraceptive option.
Because it is long-acting and does not require daily use, the medication has been prescribed for decades. Multiple meningioma birth control claims have been filed with allegations against the product.
Depo-Provera Brain Tumor Lawsuit
The main allegation is that Depo-Provera may increase the risk of developing meningiomas, a type of tumor that forms in the membranes surrounding the brain and spinal cord. While many meningiomas are noncancerous, they can still lead to serious complications, including:
- Cognitive difficulties
- Seizures
- Vision impairment
- Neurological damage
Plaintiffs in the Depo-Provera lawsuit allege that long-term use of the drug may increase this risk and that they were not adequately warned.
Differences in U.S. and International Depo-Provera Warning Labels
One of the most significant allegations in the Depo-Provera lawsuit involves differences in product labeling across countries. The complaint claims that:
- Canadian labeling has referenced meningioma as a potential adverse reaction
- Warnings about meningioma risks appear in labeling in the European Union and United Kingdom
- U.S. labeling has not included the same level of warning
This discrepancy is central to failure-to-warn claims, which focus on whether manufacturers provided adequate information to consumers and healthcare providers. There was no updated Depo-Provera labeling until the end of 2025.
Scientific Research and Ongoing Debate
As with many pharmaceutical cases, Depo-Provera litigation involves ongoing scientific debate. Research by the National Library of Medicine suggests an association between injectable medroxyprogesterone use and meningioma.
Tests have explored whether prolonged exposure to certain hormones may influence tumor growth. Medical experts have also noted that certain tumors may respond to hormonal activity, which is still an area of active research.
While studies are ongoing, manufacturers have maintained that the medication is safe when used as directed. Courts will evaluate competing evidence as cases proceed.
How Courts Are Managing Depo-Provera Lawsuits
Because dangerous drug lawsuits are being filed nationwide, many cases are being handled through multidistrict litigation (MDL). This allows courts to coordinate similar claims. Courts overseeing these cases have structured procedures to efficiently manage large volumes of claims.
In many mass tort cases involving dangerous drugs, plaintiffs are required to provide documentation showing use of the drug and a qualifying diagnosis. This early review process helps make sure that claims moving forward are supported by basic evidence.
Obtaining Records for the Depo Shot Lawsuit in 2026
Because some individuals used Depo-Provera many years ago, obtaining medical records can be challenging.
Courts have acknowledged this issue and, in some cases, allow alternative forms of documentation when people can show reasonable efforts were made to locate records.
Meningioma Birth Control Claims
Depo-Provera lawsuits typically involve several legal theories:
Failure to Warn
Plaintiffs allege that the manufacturer did not adequately disclose potential risks.
Product Liability
Product liability claims involving dangerous pharmaceuticals focus on whether the drug can be considered unsafe due to undisclosed risks.
Negligence
Some cases allege that the manufacturer failed to properly monitor safety data or update warnings.
Safer Alternatives in Dangerous Drug Lawsuits
The lawsuit also raises questions about whether safer alternatives were available. According to the complaint, a lower-dose version of the medication existed but was not emphasized or recommended in the same way.
This argument may play a role in how courts evaluate whether the product’s design was appropriate.
Pfizer Responds to the Allegations
Pfizer has stated that it believes the claims are without merit and has indicated it will defend against the allegations. The company has also maintained that Depo-Provera has been used by millions of patients and remains an important option for reproductive health.
Statements like these are common in pharmaceutical litigation. Manufacturers and plaintiffs often present competing interpretations of safety data, so cases are reviewed carefully.
Challenges in Depo-Provera Lawsuits
Cases like meningioma birth control claims can be complicated for several reasons:
- Scientific evidence may be interpreted differently
- Long-term exposure can be difficult to evaluate
- Documentation requirements can vary
Courts must also consider both medical research and regulatory standards when evaluating claims.
Moving Forward from the Depo Shot Lawsuit in 2026
Depo-Provera litigation is still developing, but several trends are emerging as courts manage large numbers of claims. Early rulings could shape how meningioma birth control claims proceed.
Scientific evidence will play a crucial role in many of these cases as more studies conclude. Outcomes may depend heavily on how courts evaluate both medical research and legal arguments.
Speak With The Carlson Law Firm
If you or a loved one developed a brain tumor after using Depo-Provera, you may have legal options. An attorney can help review your medical history and evaluate whether a Depo-Provera lawsuit may be possible.
The Carlson Law Firm works with individuals and families in complex dangerous drug and mass tort cases. Speak with a lawyer to better understand your rights and what legal options you could have.
